Related Experiment Video
Updated: Apr 14, 2026
08:16
Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
Published on: June 17, 2015
19.5K
Exogenous β-amyloid peptide interferes with GLUT4 localization in neurons
Leandro T Oliveira1, Gabbriela V O Leon2, D William Provance3
1Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, RJ 21944-590, Brazil; School of Physical Education and Sports, Federal University of Rio deJaneiro, RJ 21944-590, Brazil.
Brain Research
|April 28, 2015
Summary
Alzheimer's disease (AD) impacts glucose metabolism by altering the distribution of the glucose transporter GLUT4. Amyloid-beta 42 peptide entry into neurons affects GLUT4, potentially explaining metabolic changes in AD.
Area of Science:
- Neuroscience
- Metabolic Diseases
- Aging Research
Background:
- Aging is a primary risk factor for diabetes and Alzheimer's disease (AD).
- Diabetes is a known risk factor for AD, but the impact of AD on diabetes remains understudied.
- The amyloid-beta 42 (Aβ42) peptide, central to AD pathology, affects neuronal function and molecular motors.
Purpose of the Study:
- To investigate the effect of Aβ42 peptide entry into neurons on the glucose transporter GLUT4.
- To explore the relationship between Aβ42, myosin Vb, and glucose metabolism in the context of AD.
- To identify potential therapeutic targets for mitigating AD-related metabolic dysfunction.
Main Methods:
- Utilized cultured chick retinal neurons to study the effects of Aβ42 peptide.
- Examined the intracellular distribution and cell surface levels of GLUT4.
- Investigated the colocalization of Aβ42 with the molecular motor myosin Vb.
- Assessed the influence of Aβ40 on Aβ42 internalization.
Main Results:
- Aβ42 peptide entry into neurons altered GLUT4 distribution and reduced its cell surface levels.
- Increased colocalization of GLUT4 with myosin Vb was observed following Aβ42 exposure.
- The Aβ40 peptide was found to inhibit the internalization of the Aβ42 peptide.
- These findings suggest a mechanism linking AD pathology to altered glucose metabolism.
Conclusions:
- Aβ42 peptide disrupts normal GLUT4 function, contributing to metabolic changes seen in Alzheimer's disease.
- Myosin Vb plays a role in mediating the effects of Aβ42 on GLUT4.
- Targeting Aβ42 internalization or its interaction with myosin Vb may offer therapeutic strategies for AD progression and associated metabolic disorders.
